KPTI Karyopharm Therapeutics Inc. Stock Quote

KPTI [NASD]

Index	-	P/E	-	EPS (ttm)	-2.73	Insider Own	2.00%	Shs Outstand	73.74M	Perf Week	-16.62%
Market Cap	970.29M	Forward P/E	-	EPS next Y	-0.93	Insider Trans	-16.25%	Shs Float	66.49M	Perf Month	-19.87%
Income	-196.30M	PEG	-	EPS next Q	-0.68	Inst Own	89.60%	Short Float	23.68%	Perf Quarter	-27.37%
Sales	108.10M	P/S	8.98	EPS this Y	15.40%	Inst Trans	-4.74%	Short Ratio	5.37	Perf Half Y	-18.87%
Book/sh	0.69	P/B	17.88	EPS next Y	58.50%	ROA	-54.30%	Target Price	-	Perf Year	-49.99%
Cash/sh	3.17	P/C	3.89	EPS next 5Y	-	ROE	-182.50%	52W Range	12.32 - 28.04	Perf YTD	-20.28%
Dividend	-	P/FCF	-	EPS past 5Y	3.90%	ROI	-71.30%	52W High	-58.67%	Beta	0.62
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	236.60%	Gross Margin	97.50%	52W Low	-5.93%	ATR	0.79
Employees	432	Current Ratio	4.60	Sales Q/Q	93.90%	Oper. Margin	-	RSI (14)	24.14	Volatility	5.75% 5.14%
Optionable	Yes	Debt/Eq	3.78	EPS Q/Q	22.60%	Profit Margin	-	Rel Volume	1.02	Prev Close	12.34
Shortable	Yes	LT Debt/Eq	3.78	Earnings	Feb 11 BMO	Payout	-	Avg Volume	2.93M	Price	11.59
Recom	1.70	SMA20	-21.98%	SMA50	-24.89%	SMA200	-28.28%	Volume	2,984,049	Change	-6.08%

Jul-02-20

Initiated

Morgan Stanley

Overweight

$34

Mar-04-20

Initiated

Barclays

Overweight

$30

Jan-17-20

Downgrade

Wedbush

Outperform → Neutral

Jul-23-19

Upgrade

JP Morgan

Neutral → Overweight

$8 → $16

Jul-05-19

Reiterated

Robert W. Baird

Outperform

$15 → $25

Jul-05-19

Reiterated

H.C. Wainwright

Buy

$29 → $32

Mar-01-19

Downgrade

JP Morgan

Overweight → Neutral

$21 → $7

Feb-28-19

Reiterated

BofA/Merrill

Underperform

$15 → $5

Feb-27-19

Downgrade

BofA/Merrill

Neutral → Underperform

$15 → $5

Jan-03-19

Upgrade

BofA/Merrill

Underperform → Neutral

Dec-03-18

Initiated

B. Riley FBR

Buy

$23

Nov-09-18

Upgrade

Wedbush

Neutral → Outperform

$19

May-24-18

Downgrade

Wedbush

Outperform → Neutral

$20 → $19

Apr-02-18

Resumed

Leerink Partners

Outperform

$19

Nov-15-17

Resumed

H.C. Wainwright

Buy

$23

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$14

Sep-08-16

Reiterated

H.C. Wainwright

Buy

$15 → $16

Aug-30-16

Upgrade

Jefferies

Hold → Buy

Aug-18-16

Initiated

H.C. Wainwright

Buy

$15

Jun-28-16

Initiated

Robert W. Baird

Outperform

$16

Mar-01-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-17-21 04:05PM	Karyopharm Announces Upcoming Virtual Investor Conference Participation PR Newswire
Feb-13-21 02:04AM	Analysts Have Lowered Expectations For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Its Latest Results Simply Wall St.
Feb-12-21 10:50PM	KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI Business Wire
02:58AM	Is Karyopharm Therapeutics (NASDAQ:KPTI) Weighed On By Its Debt Load? Simply Wall St.
Feb-11-21 02:30PM	Karyopharm Therapeutics Inc (KPTI) Q4 2020 Earnings Call Transcript Motley Fool
09:46AM	Recap: Karyopharm Therapeutics Q4 Earnings Benzinga
08:45AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:26AM	The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts Benzinga
07:00AM	Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress PR Newswire
06:30AM	Karyopharm Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-04-21 09:00AM	Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021 PR Newswire
07:00AM	Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma PR Newswire
Feb-01-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-29-21 10:50PM	KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI PR Newswire
08:38AM	Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma PR Newswire
Jan-11-21 08:00AM	Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update PR Newswire -8.59%
Jan-04-21 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +9.30%
07:00AM	Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-03-21 07:00PM	Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL PR Newswire
Dec-21-20 09:29AM	Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma Zacks
Dec-20-20 07:00PM	Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy PR Newswire
Dec-18-20 10:50PM	KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI Business Wire +8.36%
10:44PM	Is KPTI A Good Stock To Buy According To Hedge Funds? Insider Monkey
11:30AM	Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy PR Newswire
Dec-15-20 07:00AM	Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Dec-14-20 02:14AM	Can You Imagine How Karyopharm Therapeutics' (NASDAQ:KPTI) Shareholders Feel About The 66% Share Price Increase? Simply Wall St.
Dec-11-20 11:08AM	Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma PR Newswire
Dec-07-20 04:05PM	Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting PR Newswire
01:30PM	Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting PR Newswire
Dec-01-20 04:05PM	Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting PR Newswire
07:00AM	Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-30-20 03:48AM	Wall Street Analysts See These 4 Stocks As Winners Moving Into December Benzinga +12.22%
Nov-25-20 07:35AM	The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga
07:00AM	Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modifications PR Newswire
Nov-20-20 10:30AM	Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting PR Newswire
Nov-12-20 07:06PM	Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet PR Newswire
Nov-10-20 07:00AM	Karyopharm to Participate at Jefferies 2020 Virtual London Healthcare Conference PR Newswire +7.06%
Nov-04-20 01:16PM	Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting PR Newswire +6.67%
Nov-03-20 08:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
07:38AM	The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga
Nov-02-20 11:31PM	Karyopharm Therapeutics Inc (KPTI) Q3 2020 Earnings Call Transcript Motley Fool
05:55PM	Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:41PM	Karyopharm Therapeutics: Q3 Earnings Insights Benzinga
04:05PM	Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress PR Newswire
04:01PM	Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma PR Newswire
02:30PM	Karyopharm Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 11:35AM	When Will Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Breakeven? Simply Wall St.
Oct-26-20 12:31PM	Earnings Preview: Karyopharm Therapeutics (KPTI) Q3 Earnings Expected to Decline Zacks
07:00AM	Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020 PR Newswire
Oct-20-20 10:00AM	Karyopharm Therapeutics Selects MediSpend's Transparency Solution PR Newswire
Oct-19-20 04:01PM	Replimune Appoints Tanya Lewis to the Board of Directors GlobeNewswire
Oct-06-20 06:44PM	Karyopharm Therapeutics Inc (KPTI): Hedge Fund Sentiment Unchanged Insider Monkey
08:00AM	Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 PR Newswire
Oct-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Sep-14-20 10:27AM	How Should Investors React To Karyopharm Therapeutics' (NASDAQ:KPTI) CEO Pay? Simply Wall St. +7.61%
09:42AM	Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020 PR Newswire
Sep-11-20 08:35AM	Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options Zacks
Sep-02-20 07:00AM	Karyopharm Announces September 2020 Virtual Investor Conference Participation PR Newswire
Sep-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-31-20 07:00AM	Karyopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors PR Newswire
Aug-21-20 08:00AM	Karyopharm's Founder, Sharon Shacham, PhD, Selected as a Finalist for the EY Entrepreneur Of The Year® 2020 Award PR Newswire
Aug-10-20 08:00AM	Kaskela Law LLC Announces Investigation of Karyopharm Therapeutics Inc. (KPTI) and Encourages Long-Term Stockholders to Contact the Firm PR Newswire
Aug-04-20 10:01PM	Karyopharm Therapeutics Inc (KPTI) Q2 2020 Earnings Call Transcript Motley Fool -6.52%
08:25AM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress PR Newswire
Aug-03-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +5.05%
Jul-29-20 02:32PM	Top Small Cap Stocks for August 2020 Investopedia
09:40AM	Does Karyopharm Therapeutics (NASDAQ:KPTI) Have A Healthy Balance Sheet? Simply Wall St.
Jul-28-20 12:33PM	Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
07:00AM	Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020 PR Newswire
Jul-27-20 08:32PM	Were Hedge Funds Right About Souring On Karyopharm Therapeutics Inc (KPTI)? Insider Monkey
Jul-20-20 07:00AM	U.S. Food and Drug Administration Accepts Karyopharms Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy GlobeNewswire
Jul-17-20 07:00AM	Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research GlobeNewswire
Jul-14-20 07:00AM	Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor) GlobeNewswire +8.42%
Jul-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-24-20 07:00AM	Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology GlobeNewswire -5.79%
Jun-23-20 11:50AM	Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL Zacks
Jun-22-20 11:25AM	Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) GlobeNewswire
Jun-21-20 02:53PM	The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Benzinga
Jun-18-20 03:34PM	Karyopharm Therapeutics Inc (KPTI): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Jun-12-20 03:58PM	Edited Transcript of KPTI earnings conference call or presentation 5-May-20 12:30pm GMT Thomson Reuters StreetEvents
07:00AM	Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting GlobeNewswire
Jun-10-20 10:04AM	Karyopharm Starts Dosing in Selinexor Study for Glioblastoma Zacks
Jun-09-20 09:00AM	Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma GlobeNewswire -5.38%
Jun-03-20 08:32AM	Are Options Traders Betting on a Big Move in Karyopharm Therapeutics (KPTI) Stock? Zacks
Jun-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -7.41%
May-29-20 07:22AM	The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant Benzinga
May-28-20 04:05PM	Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program GlobeNewswire
May-26-20 04:05PM	Karyopharm to Participate at Jefferies Virtual Healthcare Conference GlobeNewswire -6.59%
07:00AM	Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program GlobeNewswire
May-20-20 08:00AM	Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy GlobeNewswire +9.88%
May-13-20 08:00AM	Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society GlobeNewswire
May-12-20 07:00AM	Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference GlobeNewswire -6.13%
May-06-20 08:07AM	Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade Simply Wall St.
May-05-20 07:51PM	Were Hedge Funds Right About Karyopharm Therapeutics Inc (KPTI)? Insider Monkey -5.08%
05:30PM	Karyopharm Therapeutics Inc (KPTI) Q1 2020 Earnings Call Transcript Motley Fool
10:45AM	Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:11AM	Recap: Karyopharm Therapeutics Q1 Earnings Benzinga
07:00AM	Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress GlobeNewswire

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIO), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Frenkel Ran	EVP, Chief Dev. Officer	Feb 18	Sale	14.83	2,887	42,818	46,126	Feb 22 08:11 PM
Shah Jatin	EVP, Chief Medical Officer	Feb 18	Sale	14.83	1,186	17,590	51,791	Feb 22 08:12 PM
Shacham Sharon	President & CSO	Feb 18	Sale	14.83	9,495	140,822	575,126	Feb 22 08:10 PM
Shacham Sharon	President & CSO	Feb 18	Sale	14.83	9,495	140,822	776,452	Feb 22 08:10 PM
Kauffman Michael	Chief Executive Officer	Feb 18	Sale	14.83	9,495	140,822	776,452	Feb 22 08:09 PM
Kauffman Michael	Chief Executive Officer	Feb 18	Sale	14.83	9,495	140,822	575,126	Feb 22 08:09 PM
Lewis Tanya	EVP, Chief Reg. Affairs	Feb 11	Sale	15.52	2,046	31,752	4,143	Feb 17 06:49 PM
Shah Jatin	EVP, Chief Medical Officer	Feb 11	Sale	15.52	1,748	27,127	48,127	Feb 17 06:48 PM
Frenkel Ran	EVP, Chief Dev. Officer	Feb 11	Sale	15.52	2,046	31,752	39,338	Feb 17 06:47 PM
Shacham Sharon	President & CSO	Feb 11	Sale	15.52	6,601	102,441	562,821	Feb 17 06:45 PM
Shacham Sharon	President & CSO	Feb 11	Sale	15.52	6,642	103,077	764,147	Feb 17 06:45 PM
Mason Michael	SVP, CFO & Treasurer	Feb 11	Sale	15.52	2,858	44,354	5,292	Feb 17 06:46 PM
Kauffman Michael	Chief Executive Officer	Feb 11	Sale	15.52	6,642	103,077	764,147	Feb 17 06:44 PM
Kauffman Michael	Chief Executive Officer	Feb 11	Sale	15.52	6,601	102,441	562,821	Feb 17 06:44 PM
Mirza Mansoor Raza	Director	Dec 18	Option Exercise	5.43	5,000	27,150	5,000	Dec 22 06:16 PM
Mirza Mansoor Raza	Director	Dec 18	Sale	18.00	5,000	90,000	0	Dec 22 06:16 PM
Mirza Mansoor Raza	Director	Dec 07	Option Exercise	5.43	20,000	108,600	20,000	Dec 08 05:14 PM
Mirza Mansoor Raza	Director	Dec 07	Sale	16.07	20,000	321,383	0	Dec 08 05:14 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Dec 01	Option Exercise	10.42	137,061	1,428,751	82,647	Dec 03 05:17 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Dec 01	Sale	17.53	137,061	2,402,227	4,523	Dec 03 05:17 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Nov 02	Sale	14.92	772	11,518	4,523	Nov 04 04:09 PM
Lewis Tanya	EVP,Chief Reg.&Quality Officer	Oct 30	Sale	15.58	226	3,521	539	Nov 04 08:18 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Oct 13	Option Exercise	9.23	39,271	362,537	43,199	Oct 14 06:00 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Oct 13	Sale	16.86	39,271	661,969	4,649	Oct 14 06:00 PM
Shacham Sharon	President & CSO	Oct 12	Option Exercise	0.03	7,500	248	763,989	Oct 14 05:54 PM
Kauffman Michael	Chief Executive Officer	Oct 12	Option Exercise	0.03	7,500	248	763,989	Oct 14 05:56 PM
Kauffman Michael	Chief Executive Officer	Oct 12	Sale	14.89	7,500	111,683	756,489	Oct 14 05:56 PM
Shacham Sharon	President & CSO	Oct 12	Sale	14.89	7,500	111,683	756,489	Oct 14 05:54 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Sep 08	Option Exercise	6.54	10,054	65,753	14,703	Sep 10 08:49 AM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Sep 08	Sale	14.98	10,054	150,609	4,649	Sep 10 08:49 AM
DEMAREE JOHN	Chief Commercial Officer	Aug 26	Buy	14.54	7,500	109,013	7,500	Aug 27 04:00 PM
Shacham Sharon	President & CSO	Aug 17	Option Exercise	0.03	1,477	49	757,966	Aug 18 06:05 PM
Kauffman Michael	Chief Executive Officer	Aug 17	Option Exercise	0.03	1,477	49	757,966	Aug 18 06:07 PM
Kauffman Michael	Chief Executive Officer	Aug 17	Sale	15.00	1,477	22,155	756,489	Aug 18 06:07 PM
Shacham Sharon	President & CSO	Aug 17	Sale	15.00	1,477	22,155	756,489	Aug 18 06:05 PM
Kauffman Michael	Chief Executive Officer	Jul 15	Option Exercise	0.03	7,500	248	763,989	Jul 17 04:26 PM
Shacham Sharon	President & CSO	Jul 15	Option Exercise	0.03	7,500	248	763,989	Jul 17 04:24 PM
Shah Jatin	EVP, Chief Medical Officer	Jul 15	Sale	19.46	589	11,462	43,229	Nov 04 08:16 PM
Shacham Sharon	President & CSO	Jul 15	Sale	19.43	7,500	145,723	756,489	Jul 17 04:24 PM
Kauffman Michael	Chief Executive Officer	Jul 15	Sale	19.43	7,500	145,723	756,489	Jul 17 04:26 PM
Shacham Sharon	President & CSO	Jul 10	Option Exercise	4.75	7,500	35,640	562,622	Jul 13 06:43 PM
Kauffman Michael	Chief Executive Officer	Jul 10	Option Exercise	4.75	7,500	35,640	562,622	Jul 13 06:45 PM
Kauffman Michael	Chief Executive Officer	Jul 10	Sale	19.01	7,500	142,539	555,122	Jul 13 06:45 PM
Shacham Sharon	President & CSO	Jul 10	Sale	19.01	7,500	142,539	555,122	Jul 13 06:43 PM
Shacham Sharon	President & CSO	Jul 09	Option Exercise	4.75	7,500	35,640	763,989	Jul 13 06:43 PM
Kauffman Michael	Chief Executive Officer	Jul 09	Option Exercise	4.75	7,500	35,640	763,989	Jul 13 06:45 PM
Kauffman Michael	Chief Executive Officer	Jul 09	Sale	19.53	7,500	146,487	756,489	Jul 13 06:45 PM
Shacham Sharon	President & CSO	Jul 09	Sale	19.53	7,500	146,487	756,489	Jul 13 06:43 PM
Shacham Sharon	President & CSO	Jun 22	Option Exercise	0.03	7,500	248	763,989	Jun 24 04:05 PM
Kauffman Michael	Chief Executive Officer	Jun 22	Option Exercise	0.03	7,500	248	763,989	Jun 24 04:07 PM
Kauffman Michael	Chief Executive Officer	Jun 22	Sale	20.00	7,500	150,000	756,489	Jun 24 04:07 PM
Shacham Sharon	President & CSO	Jun 22	Sale	20.00	7,500	150,000	756,489	Jun 24 04:05 PM
Shacham Sharon	President & CSO	Jun 15	Option Exercise	0.03	7,500	248	763,632	Jun 17 04:05 PM
Kauffman Michael	Chief Executive Officer	Jun 15	Option Exercise	0.03	7,500	248	763,632	Jun 17 04:07 PM
Kauffman Michael	Chief Executive Officer	Jun 15	Sale	16.37	7,500	122,779	756,489	Jun 17 04:07 PM
Shacham Sharon	President & CSO	Jun 15	Sale	16.37	7,500	122,779	756,489	Jun 17 04:05 PM
Shacham Sharon	President & CSO	Jun 10	Option Exercise	4.75	7,500	35,640	562,622	Jun 11 04:36 PM
Kauffman Michael	Chief Executive Officer	Jun 10	Option Exercise	4.75	7,500	35,640	562,622	Jun 11 04:39 PM
Kauffman Michael	Chief Executive Officer	Jun 10	Sale	18.13	7,500	135,944	555,122	Jun 11 04:39 PM
Shacham Sharon	President & CSO	Jun 10	Sale	18.13	7,500	135,944	555,122	Jun 11 04:36 PM
Shacham Sharon	President & CSO	Jun 09	Option Exercise	4.75	7,500	35,640	763,989	Jun 11 04:36 PM
Kauffman Michael	Chief Executive Officer	Jun 09	Option Exercise	4.75	7,500	35,640	763,989	Jun 11 04:39 PM
Kauffman Michael	Chief Executive Officer	Jun 09	Sale	18.50	7,500	138,746	756,489	Jun 11 04:39 PM
Shacham Sharon	President & CSO	Jun 09	Sale	18.50	7,500	138,746	756,489	Jun 11 04:36 PM
Shacham Sharon	President & CSO	May 18	Option Exercise	0.03	7,500	248	763,989	May 19 05:34 PM
Kauffman Michael	Chief Executive Officer	May 18	Option Exercise	0.03	7,500	248	763,989	May 19 05:36 PM
Kauffman Michael	Chief Executive Officer	May 18	Sale	20.00	7,500	150,000	756,489	May 19 05:36 PM
Shacham Sharon	President & CSO	May 18	Sale	20.00	7,500	150,000	756,489	May 19 05:34 PM
Shacham Sharon	President & CSO	May 15	Option Exercise	0.03	7,500	248	763,989	May 19 05:34 PM
Kauffman Michael	Chief Executive Officer	May 15	Option Exercise	0.03	7,500	248	763,989	May 19 05:36 PM
Kauffman Michael	Chief Executive Officer	May 15	Sale	18.65	7,500	139,841	756,489	May 19 05:36 PM
Shacham Sharon	President & CSO	May 15	Sale	18.65	7,500	139,841	756,489	May 19 05:34 PM
Kauffman Michael	Chief Executive Officer	May 07	Option Exercise	4.75	7,500	35,640	763,989	May 11 04:19 PM
Kauffman Michael	Chief Executive Officer	May 07	Option Exercise	4.75	7,500	35,640	562,622	May 11 04:19 PM
Shacham Sharon	President & CSO	May 07	Option Exercise	4.75	7,500	35,640	562,622	May 11 04:22 PM
Shacham Sharon	President & CSO	May 07	Option Exercise	4.75	7,500	35,640	763,989	May 11 04:22 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	May 07	Option Exercise	6.54	2,946	19,267	7,595	May 11 04:25 PM
Frenkel Ran	Chief Dev Operations Officer	May 07	Sale	20.00	1,974	39,480	35,088	May 11 04:26 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	May 07	Sale	19.73	9,660	190,627	4,649	May 11 04:25 PM
Shacham Sharon	President & CSO	May 07	Sale	19.63	7,500	147,209	555,122	May 11 04:22 PM
Shacham Sharon	President & CSO	May 07	Sale	19.63	7,500	147,205	756,489	May 11 04:22 PM
Kauffman Michael	Chief Executive Officer	May 07	Sale	19.63	7,500	147,205	756,489	May 11 04:19 PM
Kauffman Michael	Chief Executive Officer	May 07	Sale	19.63	7,500	147,209	555,122	May 11 04:19 PM
Shacham Sharon	President & CSO	Apr 09	Option Exercise	4.75	10,000	47,520	565,122	Apr 10 05:06 PM
Kauffman Michael	Chief Executive Officer	Apr 09	Option Exercise	4.75	10,000	47,520	565,122	Apr 10 05:09 PM
Kauffman Michael	Chief Executive Officer	Apr 09	Sale	20.64	10,000	206,404	555,122	Apr 10 05:09 PM
Shacham Sharon	President & CSO	Apr 09	Sale	20.64	10,000	206,404	555,122	Apr 10 05:06 PM
Shacham Sharon	President & CSO	Apr 08	Option Exercise	4.75	10,000	47,520	766,489	Apr 10 05:06 PM
Kauffman Michael	Chief Executive Officer	Apr 08	Option Exercise	4.75	10,000	47,520	766,489	Apr 10 05:09 PM
Kauffman Michael	Chief Executive Officer	Apr 08	Sale	18.61	10,000	186,115	756,489	Apr 10 05:09 PM
Shacham Sharon	President & CSO	Apr 08	Sale	18.61	10,000	186,115	756,489	Apr 10 05:06 PM
Greene Barry E	Director	Mar 13	Option Exercise	0.03	3,030	100	6,030	Mar 17 05:35 PM
Kauffman Michael	Chief Executive Officer	Mar 10	Option Exercise	4.75	10,000	47,520	565,122	Mar 11 07:07 PM
Shacham Sharon	President & CSO	Mar 10	Option Exercise	4.75	10,000	47,520	565,122	Mar 11 07:10 PM
Shacham Sharon	President & CSO	Mar 10	Sale	22.22	10,000	222,186	555,122	Mar 11 07:10 PM
Kauffman Michael	Chief Executive Officer	Mar 10	Sale	22.22	10,000	222,186	555,122	Mar 11 07:07 PM
Kauffman Michael	Chief Executive Officer	Mar 09	Option Exercise	4.75	10,000	47,520	766,489	Mar 11 07:07 PM
Shacham Sharon	President & CSO	Mar 09	Option Exercise	4.75	10,000	47,520	766,489	Mar 11 07:10 PM
Shacham Sharon	President & CSO	Mar 09	Sale	22.52	10,000	225,195	756,489	Mar 11 07:10 PM
Kauffman Michael	Chief Executive Officer	Mar 09	Sale	22.52	10,000	225,195	756,489	Mar 11 07:07 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience